Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma
NCT ID: NCT00189787
Last Updated: 2008-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
370 participants
INTERVENTIONAL
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
NCT00189722
A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma
NCT00116103
Study in Mild Asthmatic Patients
NCT00748306
Efficacy, Safety, and Pharmacokinetics of QAW039
NCT01253603
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
NCT00411567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tacrolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated with inhaled corticosteroid
* FEV1 (forced expiratory volume in 1 second)\>60% to 80%
Exclusion Criteria
* Asthma exacerbation within 90 days
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
R.G.M.vom Amsterdam, MD
Role: STUDY_DIRECTOR
Astellas Pharma Europe B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pleven, , Bulgaria
Rousse, , Bulgaria
Sofia, , Bulgaria
Varna, , Bulgaria
Brno, , Czechia
Krhanice, , Czechia
Olomouc, , Czechia
Šumperk, , Czechia
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Bonn, , Germany
Deggendorf, , Germany
Düsseldorf, , Germany
Hanover, , Germany
München, , Germany
Potsdam, , Germany
Rudersdorf, , Germany
Solingen, , Germany
Wiesbaden, , Germany
Budapest, , Hungary
Csorna, , Hungary
Füzesabony, , Hungary
Nyíregyháza, , Hungary
Szombathely, , Hungary
Bialystok, , Poland
Krakow, , Poland
Lodz, , Poland
Lodz, , Poland
Lublin, , Poland
Tarnów, , Poland
Wroclaw, , Poland
Moscow, , Russia
Moscow, , Russia
Rostov-on-Don, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Smolensk, , Russia
Yekaterinburg, , Russia
Dnipro, , Ukraine
Donetsk, , Ukraine
Kiev, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FG-506-17-07
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.